Standard of Care: Managing Symptoms and Long-term Health

Managing Indolent Systemic Mastocytosis (ISM) is focused on two main goals: reducing the daily symptoms caused by mast cell “mediators” (the chemicals they release) and protecting your long-term health, particularly your bones ^[1][2].

The Step-Wise Approach to Symptom Management

Doctors typically follow a tiered approach to treatment, starting with the most basic medications and adding more specialized ones if symptoms persist ^[3][4].

1. Trigger Avoidance: The foundation of care is identifying and avoiding things that cause your mast cells to “degranulate” (leak chemicals), such as heat, stress, or certain drugs ^[4][5].
2. Antihistamines (H1 and H2 Blockers): Most patients take a combination of H1 blockers (like cetirizine) for skin and respiratory symptoms and H2 blockers (like famotidine) for stomach acid and GI issues ^[1][3].
3. Mast Cell Stabilizers: If antihistamines aren’t enough, doctors may add sodium cromolyn, which acts like a “lid” on the mast cells to keep them from releasing chemicals, particularly in the gut ^[3].
4. Prostaglandin Inhibitors: For patients who safely tolerate them, specific NSAIDs (like high-dose aspirin) are highly effective at blocking prostaglandin D2, a major cause of flushing and brain fog ^[6].
5. Leukotriene Inhibitors: Medications like montelukast may be added to help with respiratory symptoms or skin flushing ^[3].
6. Biologics (Omalizumab): For patients who suffer from frequent, severe allergic reactions (anaphylaxis) that aren’t controlled by other drugs, omalizumab may be used to reduce the frequency and severity of these events ^[7][8].

Targeted Therapies: Turning Off the “Driver”

While the treatments above manage the symptoms, targeted therapies go after the underlying cause—the overactive KIT mutation ^[9].

• Avapritinib: This is the first treatment specifically FDA-approved for adults with symptomatic ISM ^[9]. It works by directly inhibiting the KIT D816V mutation, effectively turning off the growth signal in your mast cells ^[9]. It is generally indicated for patients with moderate to severe symptoms that are inadequately controlled by standard H1/H2 blockers. In clinical trials, it significantly reduced total symptom scores, including “brain fog” and skin spots ^[10].
• Midostaurin: While primarily used for “advanced” forms of the disease, it is sometimes used off-label for ISM patients with severe symptoms. It is a “multi-kinase” inhibitor, meaning it targets several different signals in the cell, not just KIT ^[9][11].

Protecting Your Bone Health

Many patients are surprised to learn that mastocytosis can weaken the bones. Mast cells in the bone marrow release chemicals that speed up the breakdown of bone tissue, leading to osteoporosis or high risk for fractures ^[12][2].

• Monitoring: Standard care includes regular DEXA scans (bone density tests) to monitor for thinning bones ^[2].
• Treatment: If bone loss is found, doctors may prescribe bisphosphonates (like alendronate) or RANKL inhibitors (like denosumab) to strengthen the bones and prevent fractures ^[2][13].

A Note on Side Effects

Every medication has potential trade-offs. Standard antihistamines can sometimes cause sedation ^[3]. Targeted therapies like avapritinib can cause swelling (edema) or, in some cases, “neurocognitive” effects like changes in memory or thinking. Because these cognitive side effects can feel confusingly similar to the “brain fog” caused by the disease itself, it is highly recommended to establish a “cognitive baseline” with your doctor before starting treatment so you can accurately tell the difference ^[14][15]. Midostaurin is frequently associated with nausea or vomiting ^[16]. Always report new symptoms to your care team so they can adjust your dosage or strategy ^[15].